TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00917644
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 80 mg dose of marketed 80 mg atorvastatin tablets
Study: NCT04595994
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
Study: NCT00645255
Drug: sibutramine or placebo
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one capsule daily
Study: NCT01260675
Drug: Buprenorphine HCl/Naloxone HCl
Normalized name: buprenorphine HCl/naloxone HCl 8 mg-2 mg SUBLINGUAL TABLET, SUBLINGUAL
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00713310
Drug: Asacol 400 mg
Normalized name: Asacol 400 MG Delayed Release Oral Tablet
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose:~17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM
Study: NCT00713310
Drug: Asacol 400 mg
Normalized name: Asacol 400 MG Delayed Release Oral Tablet
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose:~17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM
Study: NCT00335985
Drug: GB-0998
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
Study: NCT00884767
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05464953
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema
Study: NCT05464953
Drug: Formulated Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate
Study: NCT01395290
Drug: cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.000 IU per week, oral
Study: NCT00940472
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
Study: NCT00665314
Drug: Plerixafor (AMD3100)
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.24mg/kg SC for 2 to 7 days.
Study: NCT00665314
Drug: Can be any registered nonpegylated form of G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
Study: NCT01395784
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
Study: NCT04762771
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase \> 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral
Study: NCT00493857
Drug: Nimotuzumab Humanized Monoclonal Antibody
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab 400mg every week
Study: NCT00493857
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab 400mg every 2 weeks
Study: NCT00062816
Drug: ISIS 14803, peginterferon alfa, ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00353756
Drug: C326, IL-6 Inhibitory Avimer protein
DrugBank: C326 (DB06017)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03782831
Drug: PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg intravenously every 2 weeks
Study: NCT00779259
Drug: Quinine 648 mg
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
Study: NCT00567255
Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05145270
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram(No-specified) 10-20mg/d, once per day.
Study: NCT00203814
Drug: Sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00203814
Drug: Artesunate plus sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01515020
Drug: vancomycin monotherapy
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous therapy by vancomycin
Study: NCT01515020
Drug: daptomycin monotherapy
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous therapy by daptomycin
Study: NCT02316509
Drug: GDC-0927
Normalized name: GDC-0927
DrugBank: GDC-0927 (DB14934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0927 will be administered as per schedule specified in the respective arm.
Study: NCT04121078
Drug: TAK-906
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-906 capsule.
Study: NCT02969473
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle.
Study: NCT04121078
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin infusion.
Study: NCT04136444
Drug: Padsevonil
Normalized name: Padsevonil
DrugBank: Padsevonil (DB14977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Padsevonil will be administered in predefined dosages.
Study: NCT03207165
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be initiated on Milrinone at 0.125 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[0.250, 0.375, 0.5 and \>0.5 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
Study: NCT03207165
Drug: Dobutamine
Normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be initiated on Dobutamine at 2.5 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[5.0, 7.5, 10 and \>10 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
Study: NCT00266669
Drug: Topical organogel with nitroglycerin
Normalized name: nitroglycerin Topical Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04163289
Drug: Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
Study: NCT02866955
Drug: Estramustine
Normalized name: Estramustine
DrugBank: Estramustine (DB01196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140mg/4 caps/day
Study: NCT02866955
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/day
Study: NCT02593175
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02593175
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01591902
Drug: Tesamorelin
Normalized name: Tesamorelin
DrugBank: Tesamorelin (DB08869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily 2 mg subcutaneous injections of tesamorelin
Study: NCT02606864
Drug: Nifurtimox (BAYa2502)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Intake of 4 x 30 mg nifurtimox tablets
Study: NCT00742859
Drug: betrixaban
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally, once daily for at least 3 months
Study: NCT00742859
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin will be prescribed by the investigator according to the standard of care.
Study: NCT01403948
Drug: BI 836826
Normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
Study: NCT04040491
Drug: PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
Study: NCT00892840
Drug: BMS-820836
Normalized name: BMS-820836
DrugBank: Liafensine (DB14878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
Study: NCT02086032
Drug: Dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing sleeping quality between micronised progesterone and dydrogesterone users.
Study: NCT02086032
Drug: micronized progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparing sleeping quality between micronised progesterone and dydrogesterone users
Study: NCT00329056
Drug: MitoQ
Normalized name: Mitoquinone
DrugBank: Mitoquinone (DB05063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
Study: NCT01455909
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin oral 100 mg/day
Study: NCT00799851
Drug: cyanoacrylate injection
Normalized name: ethyl cyanoacrylate
DrugBank: 2-octyl cyanoacrylate (DB12040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyanoacrylate injection
Study: NCT02058823
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
Study: NCT02058823
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
Study: NCT03363113
Drug: Botulinum Toxins
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Injection of botulinum toxin in the muscles affected by oromandibular dystonia
Study: NCT04635605
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
Study: NCT00959400
Drug: Fentanyl Transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
Study: NCT02660008
Drug: GlucaGen
Normalized name: GlucaGen
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
Study: NCT01607203
Drug: pregnyl
Normalized name: Pregnyl
DrugBank: Choriogonadotropin alfa (DB00097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5000 IU SC
Study: NCT01402336
Drug: GnRH antagonist (Cetrorelix)
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
Study: NCT01402336
Drug: Conventional GnRH agonist (Triptorelin)
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
Study: NCT01629199
Drug: rhEGF(recombinant human Epidermal Growth Factor)
Normalized name: Hu-rhEGF-rP64k/Mont
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568633
Drug: Anti-thymocyte globulin (ATG)
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg for 5 days by IV
Study: NCT00568633
Drug: Cyclosporine (CSP)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.25 mg/kg twice daily oral
Study: NCT00568633
Drug: Mycophenolate mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/kg twice daily oral
Study: NCT00568633
Drug: Methylprednisolone sodium succinate
Normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0 mg/kg for 5 days by IV
Study: NCT01967498
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01204723
Drug: Placebo Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Aprepitant 0 mg once daily for 5 days
Study: NCT01204723
Drug: Active Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Aprepitant 160 mg once daily for 5 days
Study: NCT02338570
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
Study: NCT00868816
Drug: 12 cycles of oxaliplatine based adjuvant chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
Study: NCT00868816
Drug: 8 cycles of oxaliplatine based adjuvant chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
Study: NCT02767297
Drug: FDL169
Normalized name: FDL169
DrugBank: FDL169 (DB16878)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00566202
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
Study: NCT00566202
Drug: JNJ-18038683
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
Study: NCT01239732
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m\^2 on Day 1 every 3 weeks or at a dose of 80 mg/m\^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
Study: NCT01239732
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
Study: NCT01239732
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
Study: NCT01779791
Drug: PCI-32765 (Ibrutinib)
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
Study: NCT02917057
Drug: exenatide once weekly
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide treatment in customary clinical care in the USA
Study: NCT02917057
Drug: basal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: basal insulin tretament in the customary clinical care in USA
Study: NCT01948856
Drug: J022X ST
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals
Study: NCT04458324
Drug: Buspirone Hydrochloride
Normalized name: Buspirone Hydrochloride
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take 30 mg buspirone HCl twice a day for 6 months.
Study: NCT04526821
Drug: Bovine Lactoferrin
Normalized name: Bovine lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine Lactoferrin 600mg daily for 12 weeks (3 chewable tablets of 100mg , twice a day), for 12 weeks plus personal portection provided from the hospital.
Study: NCT00798278
Drug: Urokinase
Normalized name: Urokinase
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest tube with intrapleural urokinase infusion for 3 days
Study: NCT03265223
Drug: 0.2% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal instillation versus intraincisional infiltration
Study: NCT03062254
Drug: radium-223 dichloride
Normalized name: radium-223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 doses of Radium-223
Study: NCT03618589
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
Study: NCT01265875
Drug: Human Secretin
Normalized name: Human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Escalation
Study: NCT01397734
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.